Clinical Trials Logo

Clinical Trial Summary

Suicide is the leading cause of death among young people (YP) aged 10 to 25 years in the Netherlands. In addition, YP report high rates of suicidal ideation (16%). While suicidal behavior is a complex phenomenon with many factors and causes, the role of social media is becoming more prominent, especially for YP. Social media has been shown to be a source where YP can find support, but it's also a place where suicidal behavior is glorified or normalized, which can be triggering or harmful to other social media consumers. The #Chatsafe guidelines were developed by Orygen Australia to better equip young people to communicate safely about suicide on social media. These guidelines are supported by a social media campaign to make the content of the guidelines more accessible to them. The #Chatsafe intervention consists of both the guidelines and the social media campaign. A small-scale Australian feasibility study showed promising results in terms of the acceptance and safety of the campaign, and safety regarding communicating about suicide on social media platforms. Currently, in Australia it is tested to what extent these results hold up in a Randomized Controlled Trial (RCT) (Robinson et al., 2023). With funding from the Dutch National Agenda for Suicide Prevention, a contextualized replication study is conducted. The aim of this study is to determine whether the #Chatsafe intervention has an effect on the way in which Dutch YP communicate online about suicide.


Clinical Trial Description

The #Chatsafe guidelines were developed by Orygen to better equip YP to communicate safely about suicide on social media. These guidelines are supported by a national social media campaign to make the content of the guidelines more accessible to the target group. The #Chatsafe intervention consists of both the guidelines and a social media campaign. A small-scale Australian feasibility study showed promising results in terms of acceptance and safety of the campaign, as well as the willingness of young people to intervene against suicide, their perceived self-efficacy, confidence, and safety regarding communicating about suicide on social media platforms. To test whether the effects hold up in a controlled setting, a Randomized Controlled Trial (RCT) is conducted. With funding from the Dutch National Agenda for Suicide Prevention, commissioned by 113 Suicide Prevention, the #Chatsafe campaign is being translated to fit the Dutch context through a co-design process involving end users. To investigate whether this campaign has the intended effect in the Netherlands, a contextualized replication study into the efficacy of ChatsafeNL (Chatsafe Netherlands) is conducted in a controlled setting. The aim of the research is to determine whether the #ChatsafeNL intervention affects how YP, both with and without suicidal ideation, communicate online about suicide. A group receiving #ChatsafeNL content (intervention group) will be compared with a group who received content about sexual health and wellbeing (control group). In the current study, the efficacy of the #ChatsafeNL intervention is tested in an RCT. The intervention condition (#ChatsafeNL social media intervention) is compared with a control intervention (sexual health campaign). The intervention phase lasts 8 weeks. Participants will be recruited over a period of 6-12 months. Participants are asked to complete a self-report questionnaire at three different times, namely prior to the intervention (baseline, T1), immediately after the 8-week intervention (T2) and 4 weeks post-intervention (T3). During the intervention period, participants receive campaign content every week for 8 weeks. They are offered a short questionnaire to monitor safety and assess the evaluation of the content. Initially, the campaign is developed for Instagram. This may expand to other social media platforms later on. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06364332
Study type Interventional
Source 113 Suicide Prevention
Contact Elke Elzinga, dr
Phone 020 3113883
Email e.elzinga@113.nl
Status Recruiting
Phase N/A
Start date April 8, 2024
Completion date March 2025

See also
  Status Clinical Trial Phase
Completed NCT05203146 - PIMPmyHospital: a Mobile App to Improve Emergency Care Efficiency and Communication N/A
Completed NCT04105751 - Testing a Novel Manual Communication System for Mechanically Ventilated ICU Patients N/A
Completed NCT04595695 - The Effect of Clear Masks in Improving Patient Relationships N/A
Completed NCT05540444 - RadConnect Communication Application
Recruiting NCT04317664 - Intervention to Improve Driving Practices Among High-Risk Teen Drivers Phase 3
Completed NCT05812599 - Understanding COVID-19 Testing Knowledge and Practices Among 2-1-1 Helpline Callers N/A
Completed NCT03221985 - ESM Pilot: Mobile Phones and Psychology N/A
Completed NCT02267265 - Pilot Study of Novel Postpartum Educational Video Intervention N/A
Completed NCT03203018 - Health Literacy and Cardiovascular Knowledge Workshop in Women From Disadvantaged Communities N/A
Completed NCT02695316 - Barrier-free Communication in Maternity Care of Allophone Migrants N/A
Completed NCT02619474 - The Effect of Whiteboards on Patient Satisfaction N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Completed NCT01697137 - Patient and Physician Intervention to Increase Organ Donation N/A
Completed NCT01459744 - An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations N/A
Recruiting NCT01170000 - Timely End-of-Life Communication to Parents of Children With Brain Tumors N/A
Completed NCT01040975 - Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight N/A
Completed NCT03044145 - The Cultural Formulation Interview-Engagement Aid N/A
Recruiting NCT04533126 - Channels of Communication & Brain Functioning: Pilot fMRI Study
Withdrawn NCT03901547 - Emotion Regulation and Burnout Impact on Communication Documentation N/A
Completed NCT06081660 - Advance Care Planning for Older Latinos With Chronic Illness N/A